Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v3.21.2
Subsequent Events (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Nov. 03, 2021
Oct. 06, 2021
Oct. 21, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2017
Dec. 31, 2015
Subsequent Event [Line Items]                  
Revenue from contracts with customers       $ 550 $ 200 $ 1,094 $ 753    
Novartis International [Member] | License Agreement [Member]                  
Subsequent Event [Line Items]                  
Revenue from contracts with customers     $ 25,000 $ 0 $ 0 $ 0 $ 0 $ 10,000 $ 37,000
Subsequent Event [Member] | Affitech | Commercial payment purchase agreement                  
Subsequent Event [Line Items]                  
Amount of purchase price payment   $ 6,000              
Payments eligible to receive as a percent of net sales   0.50%              
Period over which entity is entitled to receive payments   10 years              
Subsequent Event [Member] | Affitech | Commercial payment purchase agreement | Maximum [Member]                  
Subsequent Event [Line Items]                  
Potential future cash payments   $ 20,000              
Subsequent Event [Member] | Novartis International [Member] | License Agreement [Member]                  
Subsequent Event [Line Items]                  
Revenue from contracts with customers $ 35,000